Last 7 days
5.4%
Last 30 days
-5.7%
Last 90 days
-8.5%
Trailing 12 Months
20.7%
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
JNJ | 404.8B | 94.9B | -5.16% | -10.64% | 22.56 | 4.26 | 1.25% | -14.07% |
LLY | 296.8B | 28.5B | -5.67% | 20.74% | 47.53 | 10.4 | 0.79% | 11.88% |
MRK | 272.8B | 59.3B | -1.75% | 40.02% | 17.88 | 4.63 | 21.72% | 11.27% |
PFE | 226.4B | 100.3B | -8.43% | -20.95% | 7.22 | 2.26 | 23.43% | 42.74% |
BMY | 142.7B | 46.2B | -7.78% | -1.12% | 22.55 | 3.09 | -0.49% | -9.54% |
MID-CAP | ||||||||
PRGO | 4.8B | 4.5B | -0.20% | -5.41% | -34.17 | 1.08 | 7.56% | -104.06% |
RETA | 3.3B | 2.2M | 105.10% | 171.03% | -10.52 | 1.5K | -80.71% | -4.88% |
SMALL-CAP | ||||||||
SUPN | 1.9B | 667.2M | -9.96% | 17.66% | 31.57 | 2.87 | 15.09% | 13.64% |
TLRY | 1.6B | 602.5M | -17.77% | -52.80% | -2.74 | 2.63 | 18.18% | -18.59% |
CGC | 991.7M | 478.9M | -11.35% | -65.42% | -0.32 | 2.07 | -31.50% | -634.70% |
INVA | 792.9M | 285.2M | -7.22% | -37.95% | 3.6 | 2.78 | -27.21% | -40.28% |
CRON | 768.8M | 114.5M | -15.28% | -37.42% | -4.56 | 6.72 | 27.90% | 57.40% |
ACRS | 541.5M | 29.8M | -40.95% | -47.43% | -6.23 | 18.2 | 340.05% | 4.35% |
OCUL | 400.7M | 51.5M | -2.49% | -0.39% | -5.64 | 7.78 | 18.32% | -984.05% |
ENDP | 94.1M | 2.3B | -43.99% | -88.43% | -0.03 | 0.04 | -22.53% | -376.66% |
Income Statement (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Revenue | -2.4% | 28,541 | 29,240 | 29,071 | 29,323 | 28,318 |
S&GA Expenses | 0.8% | 6,440 | 6,389 | 6,353 | 6,414 | 6,432 |
R&D Expenses | 1.4% | 7,191 | 7,093 | 6,996 | 6,869 | 6,931 |
EBITDA | 2.3% | 8,329 | 8,143 | 7,842 | 8,366 | - |
EBITDA Margin | 4.8% | 0.29* | 0.28* | 0.27* | 0.29* | - |
Earnings Before Taxes | 3.9% | 6,806 | 6,550 | 6,230 | 6,733 | 6,156 |
EBT Margin | 6.5% | 0.24* | 0.22* | 0.21* | 0.23* | - |
Net Income | 3.5% | 6,245 | 6,033 | 5,692 | 6,129 | 5,582 |
Net Income Margin | 6.0% | 0.22* | 0.21* | 0.20* | 0.21* | - |
Free Cahsflow | -7.5% | 7,084 | 7,661 | 7,108 | 8,063 | - |
Balance Sheet | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Assets | 4.3% | 49,490 | 47,462 | 47,064 | 46,919 | 48,806 |
Current Assets | 2.2% | 18,035 | 17,640 | 17,115 | 16,965 | 18,452 |
Cash Equivalents | -21.0% | 2,067 | 2,617 | 2,623 | 2,459 | 3,819 |
Inventory | 12.5% | 4,310 | 3,831 | 3,899 | 3,893 | 3,886 |
Net PPE | 8.9% | 10,144 | 9,311 | 9,128 | 9,103 | 8,985 |
Goodwill | 4.7% | 4,073 | 3,892 | 3,892 | 3,892 | 3,892 |
Current Liabilities | 9.5% | 17,138 | 15,653 | 15,621 | 13,386 | 15,053 |
LT Debt, Non Current | 4.2% | 14,738 | 14,144 | 14,692 | 15,153 | 15,346 |
Shareholder's Equity | 5.8% | 10,650 | 10,070 | 8,545 | 9,331 | 8,979 |
Retained Earnings | 0.4% | 10,043 | 10,007 | 8,556 | 9,369 | 8,959 |
Additional Paid-In Capital | 1.4% | 6,921 | 6,829 | 6,746 | 6,656 | 6,833 |
Accumulated Depreciation | -0.5% | 10,074 | 10,120 | 10,138 | 9,977 | - |
Shares Outstanding | 0.0% | 901 | 900 | 904 | - | - |
Minority Interest | 31.1% | 126 | 96.00 | 115 | 131 | 176 |
Cashflow (Last 12 Months) | (In Millions) | |||||
---|---|---|---|---|---|---|
Description | (%) Q/Q | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 |
Cashflow From Operations | -7.5% | 7,084 | 7,661 | 7,108 | 8,063 | 7,261 |
Share Based Compensation | 5.0% | 371 | 354 | 359 | 358 | 343 |
Cashflow From Investing | -17.3% | -3,261 | -2,780 | -2,473 | -2,492 | -2,762 |
Cashflow From Financing | 6.6% | -5,406 | -5,791 | -4,991 | -5,951 | -4,131 |
Dividend Payments | 3.2% | 3,536 | 3,425 | 3,313 | 3,198 | 3,087 |
Buy Backs | -33.3% | 1,500 | 2,250 | 2,250 | 2,750 | 1,250 |
14.2%
0%
0%
Y-axis is the maximum loss one would have experienced if Eli Lilly and was unfortunately bought at previous high price.
22.4%
26.7%
34.9%
35.2%
FIve years rolling returns for Eli Lilly and.
Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
2023-03-15 | B. Riley Wealth Advisors, Inc. | added | 11.47 | 3,006,020 | 14,514,000 | 0.41% |
2023-03-13 | Claro Advisors LLC | added | 16.86 | 116,233 | 479,233 | 0.16% |
2023-03-10 | MATHER GROUP, LLC. | added | 12.78 | 410,849 | 1,897,850 | 0.04% |
2023-03-10 | VICTORY CAPITAL MANAGEMENT INC | added | 2.62 | 33,979,800 | 245,004,000 | 0.27% |
2023-03-08 | SHEETS SMITH WEALTH MANAGEMENT | reduced | -4.94 | 59,029 | 844,029 | 0.13% |
2023-03-08 | Capital Asset Advisory Services LLC | added | 21.72 | 467,373 | 1,694,370 | 0.14% |
2023-03-07 | Great Lakes Retirement, Inc. | new | - | 1,924,410 | 1,924,410 | 0.49% |
2023-03-06 | Rockefeller Capital Management L.P. | reduced | -28.89 | -47,100,000 | 193,928,000 | 0.98% |
2023-03-06 | BIRMINGHAM CAPITAL MANAGEMENT CO INC/AL | reduced | -0.51 | 681,870 | 6,105,870 | 2.32% |
2023-03-06 | Aldebaran Financial Inc. | reduced | -10.76 | 1,376 | 379,376 | 0.41% |
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Feb 09, 2023 | vanguard group inc | 7.73% | 73,429,863 | SC 13G/A | |
Feb 01, 2023 | blackrock inc. | 6.9% | 65,467,793 | SC 13G/A | |
Jan 25, 2023 | lilly endowment inc | 10.83% | 102,948,810 | SC 13G/A | |
Feb 11, 2022 | pnc financial services group, inc. | 5.42% | 51,888,455 | SC 13G/A | |
Feb 09, 2022 | vanguard group inc | 7.24% | 69,261,754 | SC 13G/A | |
Feb 08, 2022 | blackrock inc. | 6.7% | 63,877,023 | SC 13G/A | |
Jan 27, 2022 | lilly endowment inc | 11.23% | 107,463,810 | SC 13G/A | |
Feb 12, 2021 | pnc financial services group, inc. | 5.44% | 52,012,151 | SC 13G/A | |
Feb 10, 2021 | vanguard group inc | 7.18% | 68,661,494 | SC 13G/A | |
Jan 29, 2021 | blackrock inc. | 6.1% | 58,811,768 | SC 13G/A |
Fair Value | Very Pessimistic | Pessimistic | Base Case | Optimistic | Very Optimistic |
---|---|---|---|---|---|
Very Low Inflation | - - | - - | - - | - - | - - |
Current Inflation | 70.95 -78.47% | 84.47 -74.37% | 127.92 -61.18% | 174.93 -46.92% | 222.33 -32.53% |
Very High Inflation | - - | - - | - - | - - | - - |
Date Filed | Form Type | Document | |
---|---|---|---|
Mar 13, 2023 | 4 | Insider Trading | |
Mar 02, 2023 | 4 | Insider Trading | |
Mar 02, 2023 | 4 | Insider Trading | |
Mar 02, 2023 | 4 | Insider Trading | |
Mar 02, 2023 | 4 | Insider Trading | |
Mar 01, 2023 | 4 | Insider Trading | |
Feb 24, 2023 | PRE 14A | PRE 14A | |
Feb 24, 2023 | 8-K | Current Report | |
Feb 24, 2023 | 424B2 | Prospectus Filed | |
Feb 23, 2023 | 424B2 | Prospectus Filed |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
2023-03-10 | Weems Alonzo | sold | -318,850 | 318 | -1,000 | evp, erm & ceco |
2023-03-01 | Weems Alonzo | acquired | - | - | 1,779 | evp, erm & ceco |
2023-03-01 | Hernandez Edgardo | acquired | - | - | 1,890 | evp & pres., mfg. operations |
2023-03-01 | Dozier Eric | sold (taxes) | -222,211 | 311 | -714 | evp, hr & diversity |
2023-03-01 | Weems Alonzo | sold (taxes) | -246,797 | 311 | -793 | evp, erm & ceco |
2023-03-01 | Dozier Eric | acquired | - | - | 1,602 | evp, hr & diversity |
2023-03-01 | Hernandez Edgardo | sold (taxes) | -262,358 | 311 | -843 | evp & pres., mfg. operations |
2023-02-27 | Zakrowski Donald A | sold | -193,482 | 322 | -600 | svp, finance, & cao |
2023-02-21 | Hedley Mary Lynne | acquired | 9,825 | 327 | 30.00 | - |
2023-02-21 | JOHNSON KIMBERLY H | acquired | 9,825 | 327 | 30.00 | - |
Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Millions | 12 Months Ended | ||
---|---|---|---|
Dec. 31, 2022 | Dec. 31, 2021 | Dec. 31, 2020 | |
Income Statement [Abstract] | |||
Revenue (Note 2) | $ 28,541.4 | $ 28,318.4 | $ 24,539.8 |
Costs, expenses, and other: | |||
Cost of sales | 6,629.8 | 7,312.8 | 5,483.3 |
Research and development | 7,190.8 | 6,930.7 | 5,976.3 |
Marketing, selling, and administrative | 6,440.4 | 6,431.6 | 6,121.2 |
Acquired in-process research and development and development milestones (Note 3) | 908.5 | 970.1 | 769.8 |
Asset impairment, restructuring, and other special charges (Note 5) | 244.6 | 316.1 | 131.2 |
Other—net, (income) expense (Note 18) | 320.9 | 201.6 | (1,171.9) |
Costs, expenses, and other | 21,735.0 | 22,162.9 | 17,309.9 |
Income before income taxes | 6,806.4 | 6,155.5 | 7,229.9 |
Income taxes (Note 14) | 561.6 | 573.8 | 1,036.2 |
Net income | $ 6,244.8 | $ 5,581.7 | $ 6,193.7 |
Earnings per share: | |||
Basic (in dollars per share) | $ 6.93 | $ 6.15 | $ 6.82 |
Diluted (in dollars per share) | $ 6.90 | $ 6.12 | $ 6.79 |
Shares used in calculation of earnings per share: | |||
Basic (in shares) | 901,736 | 906,963 | 907,634 |
Diluted (in shares) | 904,619 | 911,681 | 912,505 |
Consolidated Balance Sheets - USD ($) $ in Millions | Dec. 31, 2022 | Dec. 31, 2021 |
---|---|---|
Current Assets | ||
Cash and cash equivalents (Note 7) | $ 2,067.0 | $ 3,818.5 |
Short-term investments (Note 7) | 144.8 | 90.1 |
Accounts receivable, net of allowances of $16.0 (2022) and $22.5 (2021) | 6,896.0 | 6,672.8 |
Other receivables | 1,662.9 | 1,454.4 |
Inventories (Note 6) | 4,309.7 | 3,886.0 |
Prepaid expenses and other current assets | 2,954.1 | 2,530.6 |
Total current assets | 18,034.5 | 18,452.4 |
Investments (Note 7) | 2,901.8 | 3,212.6 |
Goodwill (Note 8) | 4,073.0 | 3,892.0 |
Other intangibles, net (Note 8) | 7,206.6 | 7,691.9 |
Deferred tax assets (Note 14) | 2,792.9 | 2,489.3 |
Property and equipment, net (Note 9) | 10,144.0 | 8,985.1 |
Other noncurrent assets | 4,337.0 | 4,082.7 |
Total assets | 49,489.8 | 48,806.0 |
Current Liabilities | ||
Short-term borrowings and current maturities of long-term debt (Note 11) | 1,501.1 | 1,538.3 |
Accounts payable | 1,930.6 | 1,670.6 |
Employee compensation | 1,059.8 | 958.1 |
Sales rebates and discounts | 8,784.1 | 6,845.8 |
Dividends payable | 1,017.2 | 885.5 |
Income taxes payable (Note 14) | 475.1 | 126.9 |
Other current liabilities | 2,370.3 | 3,027.5 |
Total current liabilities | 17,138.2 | 15,052.7 |
Other Liabilities | ||
Long-term debt (Note 11) | 14,737.5 | 15,346.4 |
Accrued retirement benefits (Note 15) | 1,305.1 | 1,954.1 |
Long-term income taxes payable (Note 14) | 3,709.6 | 3,920.0 |
Deferred tax liabilities (Note 14) | 87.3 | 1,733.7 |
Other noncurrent liabilities | 1,736.7 | 1,644.3 |
Total other liabilities | 21,576.2 | 24,598.5 |
Commitments and Contingencies (Note 16) | ||
Eli Lilly and Company Shareholders' Equity (Notes 12 and 13) | ||
Common stock—no par value Authorized shares: 3,200,000 Issued shares: 950,632 (2022) and 954,116 (2021) | 594.1 | 596.3 |
Additional paid-in capital | 6,921.4 | 6,833.4 |
Retained earnings | 10,042.6 | 8,958.5 |
Employee benefit trust | (3,013.2) | (3,013.2) |
Accumulated other comprehensive loss (Note 17) | (3,844.6) | (4,343.1) |
Cost of common stock in treasury | (50.5) | (52.7) |
Total Eli Lilly and Company shareholders' equity | 10,649.8 | 8,979.2 |
Noncontrolling interests | 125.6 | 175.6 |
Total equity | 10,775.4 | 9,154.8 |
Total liabilities and equity | $ 49,489.8 | $ 48,806.0 |